Showing 2661-2670 of 7278 results for "".
- NEA Promotes Eczema Awareness Month in Octoberhttps://practicaldermatology.com/news/nea-promotes-eczema-awareness-month-october/2468331/The National Eczema Association (NEA) will present Eczema Awareness Month throughout October to spread awareness about living with eczema, the organization announced in a press release. This year's awareness campaign puts eczema on display with real, up-close photos of community members' f
- Study Links Radioactive Iodine Therapy to Increased Melanoma Riskhttps://practicaldermatology.com/news/study-links-radioactive-iodine-therapy-increased-melnoma-risk/2468325/A new study found elevated risk of melanoma and other nonkeratinocyte skin cancers in patients with primary thyroid cancer who received radioactive iodine therapy, particularly in the head and neck region. In the JAMA Network Open article “Development of Melanoma and Other Nonkeratinocyte
- Survey: Majority of Physicians Report Feelings of Burnouthttps://practicaldermatology.com/news/survey-majority-physicians-report-feelings-burnout/2468314/A majority of physicians reported feelings of burnout in 2024, according to a new survey. Researchers for the 2024 Survey of America's Current and Future Physicians, which focuses on the state of physician, resident, and medical student wellbeing, included 1,723 responses and co
- SEEN Hair Care Closes $9 Million in Series A Fundinghttps://practicaldermatology.com/news/seen-hair-care-closes-9-million-series-funding/2468305/SEEN, the award-winning haircare brand developed by dermatologist Iris Rubin, MD, has closed a $9 million Series A funding. The company said in a press release that this investment will “accelerate SEEN's growth as the premier science-backed, clinically-proven beauty brand, which sits at the inte
- Lebrikizumab Shows Sustained AD Control Up to 3 Years in More 80%https://practicaldermatology.com/news/lebrikizumab-shows-sustained-ad-control-3-years-more-80/2468297/More than 80% of adults and adolescents with moderate-to-severe atopic dermatitis who responded to lebrikizumab treatment at Week 16 in the ADvocate 1 and 2 monotherapy trials and continued treatment for up to 3 years experienced sustained skin clearance with monthly maintenance dosing, Almirall
- Frontier Acquires Mohs Specialist Doherty Dermatologyhttps://practicaldermatology.com/news/frontier-acquires-mohs-specialist-doherty-dermatology/2468264/Frontier Dermatology announced the acquisition of Doherty Dermatology, a clinic in Bellingham, Washington, that specializes in Mohs micrographic surgery. Doherty Dermatology will be rebranded as Frontier Dermatology (Bellingham South) starting October 1, joining the company's 35 other physician o
- Researchers Analyze Social Media Posts on JAK Inhibitorshttps://practicaldermatology.com/news/researchers-analyze-social-media-posts-jak-inhibitors/2468227/An analysis of social media posts concluded that patients are most concerned about the efficacy and side effects of JAK inhibitors and issues regarding access to them, according to a new Archive of Dermatological Research article by members of the University of Nebraska Medical Center’s Departmen
- Organon to Acquire VTAMA Maker Dermavanthttps://practicaldermatology.com/news/organon-acquire-vtama-maker-dermavant/2468226/Organon and Dermavant Sciences Ltd. announced that they have entered into a definitive agreement, under which Organon will acquire Dermavant, a Roivant company whose product VTAMA® (tapinarof) cream, 1%, for the topical treatment of mild, moderate, and severe plaque psoriasis in adults was approv
- Tralokinumab-ldrm 300 mg/2 mL Single-Dose Autoinjector Available in UShttps://practicaldermatology.com/news/tralokinumab-ldrm-300-mg2-ml-single-dose-autoinjector-available-us/2468195/The Adbry® (tralokinumab-ldrm) 300 mg/2 mL single-dose autoinjector is now available in the United States for patients 12 and older with moderate-to-severe atopic dermatitis (AD) whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisab
- Age-related Fibroblast Changes Drive Melanoma in Males, Study Sayshttps://practicaldermatology.com/news/age-related-fibroblast-changes-drive-melanoma-males-study-says/2468115/Age-related changes in fibroblasts contribute to development of aggressive, treatment-resistant melanoma in males, according to a Johns Hopkins Kimmel Cancer Center study published in Cell. The authors of the study, Dr. Ashani Weeraratna and colleagues, had previously shown in studies that